This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cervantes F, Mesa R, Barosi G . New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377–383.
Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838.
Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.
Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L, et al., Swedish Group for Myeloproliferative Disorders. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367–373.
Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.
Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.
Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1161–1168.
Kroger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhauser M, et al., MDS-subcommittee of the chronic Leukemia Working Party of the European group for Blood and Marrow Transplantation. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719–1722.
Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF . Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007; 92: 1004–1006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
George, B., Kerridge, I., Gottlieb, D. et al. A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis. Bone Marrow Transplant 42, 567–568 (2008). https://doi.org/10.1038/bmt.2008.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.219
This article is cited by
-
Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
Bone Marrow Transplantation (2016)
-
Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
Current Hematologic Malignancy Reports (2010)